Enhancement and Availability

Allogeneic CAR-T

Can Allogeneic Cell Therapy Solve the CAR-T Access Problem?

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Child Formulation

The Pediatric Formulation Gap

Pharma's Almanac

Pediatric Oncology

Why Pediatric Oncology Needs Its Own Drug Development Paradigm

David Alvaro, Ph.D.

Pharma's Almanac

Development CDMO

The Case for Earlier CDMO Involvement in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

TPDs

Low Dose, High Impact: Microdosing, Content Uniformity, and Precision Control in TPDs

David O’Connell

PCI Pharma Services

MPS

What Will It Take for Organ-on-Chip Data to Replace Animal Studies?

David Alvaro, Ph.D.

Pharma's Almanac

Chinese Biopharma

Pharmaceutical Innovation in China Takes Center Stage

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Potency Assurance

Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development

David Alvaro, Ph.D.

Pharma's Almanac

Preparedness

Preparing Manufacturing Networks for the Next Pandemic

Pharma's Almanac

Prevention

Preventive Therapeutics Beyond Vaccines

David Alvaro, Ph.D.

Pharma's Almanac